Research programme: topical skin and hair disorder therapies - RestorGenex

Drug Profile

Research programme: topical skin and hair disorder therapies - RestorGenex

Alternative Names: HYG 102440; HYG 104; HYG 112; HYG 113; HYG 201; HYG 202; HYG 302; HYG 401; HYG 420; HYG 430; HYG-102440 (combination of HYG-102 and HYG-440); HYG-114; HYG-301; HYG-410; HYG-440; RES 102440; RES 440

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hygeia Therapeutics
  • Class Estradiol congeners; Hormones
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acne; Alopecia; Hirsutism; Skin disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acne in USA (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia in USA (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hirsutism in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top